# Alcohol Withdrawal Syndrome

Alcohol withdrawal syndrome requires early risk stratification, serial clinical assessment, benzodiazepine-based treatment for clinically significant withdrawal, supportive correction of nutritional and metabolic complications, and deliberate transition to treatment for alcohol use disorder.

**Clinical question:** How should physicians identify, risk-stratify, treat, and safely disposition adults with alcohol withdrawal syndrome?

Updated: 2026-08-20T23:29:27.696755Z

## What matters in practice
- Alcohol withdrawal is a clinical diagnosis after cessation or substantial reduction of heavy, prolonged alcohol use plus at least 2 characteristic symptoms developing within hours to days; alternative causes of autonomic activation or delirium must be actively assessed.[12][21]
- A PAWSS score of 4 or greater identifies hospitalized patients at high risk for complicated withdrawal; prior withdrawal seizures or delirium, repeated detoxifications, medical instability, sedative co-exposure, and inability to participate in assessment lower the threshold for monitored inpatient care.[9][10]
- Use CIWA-Ar to quantify symptom burden only in alert, communicative patients. It is unreliable in delirium, intubation, severe medical illness, or impaired communication; do not use a low score to override a high-risk history.[9][10]
- Benzodiazepines are first-line therapy for clinically significant alcohol withdrawal and prevent seizures and delirium; symptom-triggered treatment is preferred when a validated scale can be applied reliably.[21][22]
- Acute withdrawal management is not treatment for alcohol use disorder. Initiate or arrange longitudinal AUD treatment and psychosocial support before discharge.[4][9]

## Establish the diagnosis and anticipate progression

Diagnosis is clinical; timing and trajectory guide monitoring intensity.

Alcohol withdrawal syndrome follows abrupt cessation or substantial reduction of heavy, prolonged alcohol use. Diagnostic features include autonomic hyperactivity, tremor, insomnia, nausea or vomiting, perceptual disturbances, agitation, anxiety, or generalized tonic-clonic seizures; at least 2 symptoms should develop within hours to several days, cause clinically meaningful distress or impairment, and not be better explained by another condition.[12][21]

Symptoms may begin within 6 to 24 hours after the last drink, often peak over the next 2 to 3 days, and improve over several days. Withdrawal seizures usually occur within 6 to 48 hours, whereas delirium tremens generally begins after 48 to 72 hours.[9] Withdrawal may occur despite a measurable blood alcohol concentration, particularly when the serum concentration is falling in a patient with physiologic dependence.[21]

Do not attribute fever, hypoxemia, focal neurologic findings, unexpected obtundation, severe metabolic abnormalities, or refractory agitation solely to withdrawal. Reassess for infection, trauma or intracranial injury, hypoglycemia, toxicologic syndromes, hepatic encephalopathy, pulmonary embolism, thyroid disease, medication toxicity, and non-alcohol delirium.[9]
- History that changes management: time and pattern of last alcohol use; prior withdrawal seizure, delirium, ICU admission, or repeated withdrawal episodes; concurrent benzodiazepines, barbiturates, gabapentinoids, opioids, or stimulants; medical and psychiatric comorbidity; and capacity for safe observation after discharge.[9][10]
- Examination priorities: vital signs, tremor, diaphoresis, agitation, attention and orientation, volume status, trauma, focal deficits, respiratory status, and signs of infection or liver disease.[9]

*Expected timing of major alcohol withdrawal manifestations.[9]*

| Manifestation | Typical timing after last drink | Clinical consequence |
| --- | --- | --- |
| Early autonomic and neuropsychiatric symptoms | 6-24 hours | Serial assessment; symptoms may evolve despite initially mild presentation.[9] |
| Withdrawal seizures | 6-48 hours | Treat and monitor as complicated withdrawal; investigate alternative seizure etiologies when presentation is atypical.[9] |
| Delirium tremens | Usually 48-72 hours | Requires high-acuity monitoring and aggressive treatment of withdrawal plus competing causes of delirium.[9] |

## Choose the level of care using risk, not symptom score alone

Current symptoms and future complication risk are separate decisions.

PAWSS is useful early in hospitalized patients before withdrawal fully declares itself. A score of 4 or greater indicates high risk for complicated withdrawal and may support pharmacologic prophylaxis and monitored treatment.[9][10] CIWA-Ar measures current symptom burden on a 0-to-67 scale; commonly used ranges are less than 8 for minimal to mild symptoms, 8 to 15 for moderate symptoms, and greater than 15 for severe symptoms, but protocols vary and thresholds should not be used as stand-alone disposition rules.[9]

Outpatient management is limited to carefully selected patients with mild to moderate symptoms, stable vital signs, reliable follow-up and social support, stable housing and transportation, and no history of complicated withdrawal or major unstable medical or psychiatric comorbidity.[9] Moderate symptoms may be managed outside the hospital only when these conditions are met and reassessment is assured.[9]
- Favor hospital-based care for delirium, withdrawal seizures, severe or escalating autonomic instability, respiratory compromise, uncontrolled agitation, significant diagnostic uncertainty, acute medical or surgical illness, or inability to maintain oral intake.[9]
- Favor monitored inpatient or higher-acuity care with prior delirium tremens or withdrawal seizures, PAWSS 4 or greater, repeated detoxifications, unreliable symptom reporting, pregnancy, advanced age, significant cardiopulmonary or liver disease, active infection or trauma, concurrent sedative or opioid exposure, suicide risk, severe electrolyte disturbance, polysubstance exposure, or an unsafe recovery environment.[9]
- Use CIWA-Ar only when the patient can reliably report subjective symptoms. In delirious, intubated, cognitively impaired, or medically complex patients, guide treatment by clinician assessment and objective findings rather than forcing a symptom-triggered CIWA-Ar protocol.[9]

*Practical roles of common alcohol withdrawal instruments.[9][10]*

| Instrument | Best use | Key limitation |
| --- | --- | --- |
| PAWSS | Early prediction of complicated withdrawal in hospitalized patients; score 4 or greater indicates high risk.[9][10] | Does not replace serial examination or determine the appropriate care setting by itself.[9] |
| CIWA-Ar | Serial measurement of symptom burden in alert, communicative patients.[9][21] | Poor fit for delirium, intubation, severe medical illness, or impaired communication.[9] |

## Correct reversible contributors while treating withdrawal

Supportive care prevents complications but does not replace GABAergic treatment.

Obtain bedside glucose and evaluate volume status, electrolytes, liver injury, infection, and concurrent intoxication or withdrawal according to presentation. Repeated vital signs, mental-status assessments, and medication-response assessments are essential because oversedation, progression to complicated withdrawal, or an alternate diagnosis may become apparent during the first 24 to 48 hours.[9]

Heavy alcohol use increases the risk of thiamine deficiency and Wernicke encephalopathy. Parenteral thiamine is preferred for hospitalized patients with malnutrition, vomiting, confusion, poor absorption, or severe or complicated withdrawal. In high-risk hospitalized patients, 100 mg IV or IM daily for 3 to 5 days is commonly used; suspected or manifest Wernicke encephalopathy warrants high-dose IV thiamine, commonly 200 to 500 mg IV 3 times daily for 3 to 5 days, followed by ongoing supplementation based on clinical response and local practice.[9]

Correct hypoglycemia and clinically important potassium, magnesium, and phosphate abnormalities. Magnesium replacement is appropriate for hypomagnesemia, arrhythmia, electrolyte disturbance, or prior withdrawal seizures, but magnesium is not primary therapy for alcohol withdrawal itself.[9]
- Give thiamine before glucose-containing fluids when feasible, but do not delay urgent hypoglycemia treatment.[9]
- Use oral hydration when safe; use isotonic IV fluids for clinically significant dehydration or inadequate oral intake, while individualizing volume management in heart failure, cirrhosis, and renal impairment.[9]
- Continue diagnostic reassessment if sedative requirements escalate unexpectedly or if fever, hypoxemia, focal findings, worsening metabolic derangement, or unexplained unresponsiveness develops.[9]

## Use benzodiazepines as first-line therapy

Select the regimen according to severity, monitoring capacity, and ability to assess symptoms.

Benzodiazepines are the standard first-line treatment for moderate to severe alcohol withdrawal because they relieve symptoms and reduce the risk of seizures and delirium.[9][22] Symptom-triggered treatment is preferred for most noncritically ill inpatients when trained staff can reliably perform serial CIWA-Ar assessment; compared with fixed schedules, it can reduce benzodiazepine exposure and may reduce length of stay.[21]

Common initial symptom-triggered doses cited for medical inpatients are chlordiazepoxide 25 to 50 mg, lorazepam 1 to 2 mg, or oxazepam 15 mg, with repeat assessment and titration according to the institutional protocol and patient response.[21] Benzodiazepine selection should reflect pharmacokinetics, hepatic function, age, co-exposures, and the monitoring environment. Lorazepam or oxazepam may be preferred in significant hepatic dysfunction or older adults because they undergo glucuronidation and lack active metabolites.[9][21]

Fixed-dose or front-loading approaches are appropriate when symptom scoring is unreliable or when there is a history of severe withdrawal. In severe, refractory, or delirious withdrawal, escalation should occur in a monitored setting that can manage respiratory compromise and airway intervention.[9][21]
- Monitor for oversedation, hypoventilation, aspiration, and respiratory failure, especially in cirrhosis, advanced age, chronic lung disease, or concurrent opioid or sedative exposure.[9]
- Do not use antipsychotics as stand-alone treatment for alcohol withdrawal. Haloperidol may be used adjunctively for persistent agitation or delirium after adequate benzodiazepine treatment, with attention to seizure threshold, QT prolongation, electrolytes, and interacting drugs.[21][22]
- Alpha-2 agonists or beta-blockers can attenuate autonomic symptoms but do not replace benzodiazepines for seizure or delirium prevention.[10][21]

### Phenobarbital and ICU adjuncts

Phenobarbital is increasingly used within standardized, closely monitored hospital protocols, particularly for severe or benzodiazepine-refractory withdrawal, but requires clinician familiarity and monitoring for sedation and respiratory compromise.[9] Evidence and protocols remain heterogeneous; use should be matched to local expertise and monitoring capacity.[5][9]

Dexmedetomidine can reduce adrenergic manifestations and benzodiazepine requirements in ICU-level care but does not correct the core GABAergic deficit and should not be used as sole therapy for seizure or delirium prevention.[11]

*Medication selection considerations for alcohol withdrawal.[9][21][22]*

| Approach | When it fits | Important limitation |
| --- | --- | --- |
| Symptom-triggered benzodiazepine regimen | Alert, communicative patient with reliable serial CIWA-Ar assessment and trained staff.[21] | Do not apply when delirium or medical complexity makes CIWA-Ar unreliable.[9] |
| Fixed-dose or front-loading benzodiazepine regimen | History of withdrawal delirium or when symptom assessment cannot be performed reliably.[21] | Requires close observation for accumulation and oversedation.[9][21] |
| Phenobarbital protocol | Severe or refractory withdrawal in a closely monitored setting with institutional expertise.[5][9] | Risk of sedation and respiratory compromise; protocols and evidence are heterogeneous.[5][9] |
| Adjunct haloperidol | Agitation or delirium persisting despite adequate withdrawal treatment.[21][22] | Not monotherapy; monitor QT-related risk and seizure threshold.[21][22] |

## Escalate seizures, delirium, and refractory symptoms

Complicated withdrawal is a high-acuity syndrome until alternative causes are excluded.

Alcohol withdrawal seizures and delirium tremens require urgent reassessment for competing etiologies, correction of metabolic abnormalities, and treatment in a setting capable of close respiratory and hemodynamic monitoring.[9] Benzodiazepines remain the pharmacologic foundation; antipsychotics and autonomic agents are adjuncts rather than substitutes for adequate GABAergic therapy.[21][22]

For delirium tremens, serial CIWA-Ar is generally inappropriate because patient reporting is unreliable. Guide treatment by objective agitation, autonomic instability, attention, consciousness, airway safety, and response to sedatives, while repeatedly evaluating infection, trauma, intracranial pathology, hepatic encephalopathy, hypoxia, and toxidromes.[9]
- Escalate to ICU or equivalent monitoring for refractory agitation, escalating sedative requirements, respiratory compromise, severe autonomic instability, need for continuous sedative infusions, or diagnostic uncertainty requiring intensive support.[9][11]
- Alcohol withdrawal management does not eliminate coexisting alcohol use disorder or prevent future withdrawal; link the admission to longitudinal treatment planning.[4][9]

## Use withdrawal care to initiate treatment for alcohol use disorder

Detoxification alone has no durable relapse-prevention role.

Acute withdrawal treatment should be followed by assessment and treatment planning for alcohol use disorder, including psychosocial support and recovery services.[4][8][9] For patients in early recovery or after relapse, peer, network, or 12-step facilitation may be offered as part of ongoing care.[8]

FDA-labeled pharmacotherapy may be considered once the acute withdrawal phase is addressed and patient-specific contraindications are reviewed. Acamprosate is indicated to maintain abstinence in alcohol-dependent patients who are abstinent when treatment begins and should be combined with psychosocial support.[4] Extended-release injectable naltrexone is indicated for alcohol dependence in patients able to abstain before initiation; patients should not be actively drinking at first administration and must be assessed for opioid exposure or dependence.[2]
- Acamprosate: 666 mg orally 3 times daily; reduce to 333 mg 3 times daily for creatinine clearance 30 to 50 mL/min and avoid when creatinine clearance is 30 mL/min or less.[4]
- Extended-release naltrexone: 380 mg deep IM gluteal injection every 4 weeks; evaluate opioid exposure, require an opioid-free interval of at least 7 to 10 days to avoid precipitated withdrawal, and consider overdose-reversal access because opioid tolerance is reduced after antagonist treatment ends or doses are missed.[2]
- Acamprosate and extended-release naltrexone do not treat acute alcohol withdrawal symptoms.[2][4]

*FDA-labeled relapse-prevention options supported by supplied prescribing information.[2][4]*

| Medication | Role after withdrawal | Key selection constraint |
| --- | --- | --- |
| Acamprosate | Maintenance of abstinence in patients abstinent at treatment initiation; use with psychosocial support.[4] | Renal dose reduction for creatinine clearance 30-50 mL/min; contraindicated at 30 mL/min or less.[4] |
| Extended-release naltrexone | Alcohol dependence treatment in patients able to abstain before initiation; use with psychosocial support.[2] | Avoid in current physiologic opioid dependence, acute opioid withdrawal, positive opioid screen, or failed naloxone challenge; opioid-free interval of at least 7-10 days is recommended.[2] |

## Common questions

### Can alcohol withdrawal occur with a positive blood alcohol concentration?

Yes. Withdrawal may begin while alcohol remains measurable when the concentration is falling in a physiologically dependent patient; a positive level should not defer risk assessment or treatment.[21]

### When should CIWA-Ar not be used to direct treatment?

Do not rely on CIWA-Ar in delirium, intubation, cognitive impairment, severe medical illness, or any setting where the patient cannot reliably report subjective symptoms. Use clinician assessment and objective findings instead.[9]

### Who needs inpatient alcohol withdrawal management?

Inpatient or higher-acuity care is favored for complicated withdrawal, PAWSS 4 or greater, prior seizures or delirium tremens, unstable comorbidity, concurrent sedative exposure, unreliable assessment, pregnancy, severe metabolic disturbance, or inadequate outpatient support.[9][10]

### Is phenobarbital first-line therapy for alcohol withdrawal?

Benzodiazepines remain first-line. Phenobarbital is used increasingly in standardized, closely monitored protocols for severe or refractory withdrawal, but use depends on institutional expertise and monitoring capacity.[5][9]

### Do acamprosate or naltrexone treat acute alcohol withdrawal?

No. Acamprosate is labeled for maintenance of abstinence and extended-release naltrexone for alcohol dependence treatment after appropriate abstinence and opioid assessment; neither replaces acute withdrawal treatment.[2][4]

## References
1. highlights of prescribing information — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=74b52f61-c951-4b0e-bd22-2463cb518234&type=display
2. These highlights do not include all the information needed to use VIVITROL® safely and effectively. See full prescribing information for VIVITROL.
      VIVITROL (naltrexone for extended-release injectable suspension), for intramuscular useInitial U.S. Approval: 1984 — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cd11c435-b0f0-4bb9-ae78-60f101f3703f&type=display
3. These highlights do not include all the information needed to use ZOHYDRO® ER safely and effectively. See full prescribing information for ZOHYDRO® ER.  
         
      
      ZOHYDRO® ER (hydrocodone bitartrate) extended‑release capsules, for oral use, CII
      
      Initial U.S. Approval: 1943 — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6ccfbd98-7750-4955-a654-ec104fb666f9&type=display
4. These highlights do not include all the information needed to use ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS.ACAMPROSATE CALCIUM delayed-release tablets, for oral useInitial U.S. Approval: 2004 — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=43e9ef60-2d85-4394-906b-93042fea099a
5. Use of Phenobarbital for Treating Alcohol Withdrawal — jamanetwork.com — https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2837958
6. Management of Alcohol Withdrawal Delirium: An Evidence- ... — jamanetwork.com — https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/217165
7. Diagnostic Criteria for Identifying Individuals at High Risk of ... — jamanetwork.com — https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2810438
8. The Management of Substance Use Disorders — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/M21-4011
9. Alcohol withdrawal syndrome in hospitalized patients: a practical review — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0953620526004085
10. Alcohol Withdrawal Syndrome - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/alcohol-withdrawal-syndrome
11. A rational approach to the treatment of alcohol withdrawal in the ED — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S073567571300003X
12. Managing Alcohol Withdrawal Syndrome — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0196064424001057
13. The ASAM Clinical Practice Guideline on Alcohol... : Journal of Addiction Medicine — journals.lww.com — https://journals.lww.com/journaladdictionmedicine/fulltext/2020/10000/the_asam_clinical_practice_guideline_on_alcohol.40.aspx
14. The ASAM National Practice Guideline for the... : Journal of Addiction Medicine — journals.lww.com — https://journals.lww.com/journaladdictionmedicine/fulltext/2020/04001/the_asam_national_practice_guideline_for_the.1.aspx
15. Clinical management of the alcohol withdrawal syndrome — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/add.15647
16. Alcohol withdrawal syndrome: mechanisms, manifestations ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/ane.12671
17. Severity and Treatment of Alcohol Withdrawal in Elderly ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1530-0277.1994.tb00903.x
18. A systematic review of the economic evidence surrounding ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/dar.14053
19. Management of Acute Alcohol Withdrawal Syndrome in ... — accpjournals.onlinelibrary.wiley.com — https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/phar.1770
20. Research Needs for Inpatient Management of Severe Alcohol ... — academic.oup.com — https://academic.oup.com/ajrccm/article/204/7/e61/8492399
21. Alcohol withdrawal syndrome in medical patients — www.ccjm.org — https://www.ccjm.org/content/83/1/67
22. Mental Health, Brain Health and Substance Use — www.who.int — https://www.who.int/teams/mental-health-and-substance-use/treatment-care/mental-health-gap-action-programme/evidence-centre/alcohol-use-disorders/management-of-alcohol-withdrawal
23. Study Details | NCT00229125 | Comparing the Treatment of Alcohol Withdrawal Syndrome Using Gabapentin Versus Lorazepam | ClinicalTrials.gov — clinicaltrials.gov — https://clinicaltrials.gov/study/NCT00229125
24. Study Details | NCT00106106 | Acamprosate to Reduce Symptoms of Alcohol Withdrawal | ClinicalTrials.gov — clinicaltrials.gov — https://clinicaltrials.gov/study/NCT00106106

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.